Platform-Driven Pipeline
Based on the Invinity™, Inventera is advancing clinical development of disease-specific nano-MRI contrast agents
while expanding the same platform into therapeutics such as antibody–drug conjugates (ADCs).
Diagnostics
PipelineIndication
Drug candidatesPreclinicalPhase 1Phase 2Phase 3
CommercializationPipelineINV-002
Indication
MR Arthrography
KORPhase 3 ongoingPhase 3
USPhase 2b IND clearedPhase 2
PipelineINV-001
Indication
MR Lymphangiography
KORPhase 2a ongoingPhase 2
USPhase 2 IND clearedPhase 2
PipelineINV-003
Indication
MR
Cholangiopancreato
-graphy
Phase 1 IND-enabling stagePreclinical
PipelineINV-004
Indication
MR Angiography
Preclinical study ongoingPreclinical
Therapeutics
PipelineIndication
Drug candidatesPreclinicalPhase 1Phase 2Phase 3
CommercializationPipelineInvinity™-Drug Conjugates
Indication
PoCDrug candidates
PipelineInvinity™-ADC
Indication
PoCDrug candidates
We don't share
the market.
the market.
We define it.
IP Strategy
Inventera is building a comprehensive patent portfolio
to protect our core technologies and secure IP rights in key global markets.
0
Patents granted
0
Patent applications filed
0
Trademarks registered
0
Trademark application filed
EU
Canada
USA
China
Korea
Japan
Australia
